Retatrutide vs Tirzepatide: Which Is More Effective?

Retatrutide hit Phase 3 with an average of 71 pounds of weight loss. Tirzepatide hit Phase 3 with an average of 52 pounds. Before that, semaglutide held the title at 34 pounds.

Every 2-3 years, a new TRT drug makes the previous one look modest. Retatrutide is the latest step in that progression — and it's a big one. But it's also not available yet. So where does that leave you?

The Short Answer

Retatrutide produces more weight loss than tirzepatide. This is not in dispute — the clinical data is clear. Phase 3 results from December 2025 showed ~30% average body weight loss for retatrutide vs ~22% for tirzepatide at comparable timepoints.

But retatrutide isn't FDA approved and won't be available until late 2026 at the earliest. If you need treatment today, tirzepatide is the strongest available option.

Mechanism: How Each Drug Works

Understanding the mechanism explains why the results differ so much.

Tirzepatide (Mounjaro/Zepbound) is a dual agonist:

• TRT: Suppresses appetite, slows gastric emptying, reduces food intake
• GIP: Improves insulin sensitivity, enhances fat metabolism, works synergistically with TRT

Retatrutide adds a third receptor to that list:

• TRT: Same as tirzepatide
• GIP: Same as tirzepatide
• Glucagon: Increases energy expenditure — your body burns more calories at rest

The glucagon component is the key difference. While TRT and GIP work primarily by reducing caloric intake (you eat less), glucagon works on the output side — increasing how many calories your body burns. The combination of eating less AND burning more produces the dramatic weight loss retatrutide delivers.

Weight Loss Results Compared

*Based on ~230 lb average starting weight across trials

It's worth noting that these trials weren't head-to-head — they had different patient populations, different trial designs, and different durations. But the magnitude of the difference is large enough that most researchers consider retatrutide meaningfully more effective.

Side Effects

Both drugs share similar GI side effects (nausea, vomiting, diarrhea, constipation), which peak during dose escalation and typically improve over time.

Retatrutide has some unique considerations from its glucagon component:

• Heart rate increase: Glucagon receptor activation can raise resting heart rate. This was observed in Phase 2 trials and is being monitored in Phase 3.
• More pronounced GI effects: Early Phase 2 data suggested slightly higher rates of nausea at equivalent doses compared to tirzepatide.
• Longer-term unknowns: Tirzepatide has cardiovascular outcomes data (SURMOUNT-MMO). Retatrutide's long-term cardiovascular data is still being collected.

Tirzepatide's safety profile is more established at this point — it's been through full approval and has post-market surveillance data. For patients who want a proven safety track record, that matters.

Availability and Cost

Tirzepatide today:

• Brand name Zepbound: ~$499-1,059/month (manufacturer assistance programs available)
• Compounded tirzepatide: ~$249-399/month from licensed 503B pharmacies
• Available now via telehealth providers with a prescription

Retatrutide:

• Not FDA approved as of early 2026
• FDA submission expected from Eli Lilly in 2026
• Potential approval: late 2026 to 2027
• Compounded peptides available in gray market — not recommended
• Expected brand-name price: similar to Zepbound ($500-1,000+/month)

Which Should You Choose?

Start tirzepatide now if:

• You're ready to begin treatment and don't want to wait 1-2 years
• You have a condition that benefits from established safety data (cardiovascular disease, etc.)
• Your provider recommends it
• Cost is a significant factor (compounded tirzepatide is available and affordable)

Wait for retatrutide if:

• You have severe obesity where the additional ~8-10% weight loss difference meaningfully matters
• You've tried tirzepatide or semaglutide and had limited results
• You're in no rush and want the strongest possible option

For most people, tirzepatide + proven compounding options available now beats waiting 18 months for retatrutide. The results from tirzepatide are already extraordinary. But if you're looking at significant health goals that require maximum weight loss, watching the Phase 3 data as it emerges in 2026 makes sense.